AJMC November 12, 2021
A discussion at the National Comprehensive Cancer Network 2021 Virtual Congress: Biomarkers in Solid Tumors addressed the advantages and considerations for broad and targeted genomic profiling in oncology.
Kicking off the National Comprehensive Cancer Network (NCCN) 2021 Virtual Congress: Biomarkers in Solid Tumor, co-chair Jennifer Morrissette, PhD, Abramson Cancer Center at the University of Pennsylvania, discussed considerations for use of genomic profiling in cancer, particularly how understanding the differences in capabilities and limitations of tissue vs liquid biopsies can be key in deciding which tests to order and perform for patients with solid tumors.
With all cancers having a genetic component, consisting of an accumulation of mutations in genes that regulate cell division, survival, invasion, or other hallmarks of cancer,...
Today's Sponsors
Today's Sponsor